This inventor holds 3 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Ucl Business Plc, Autolus Limited. Active years: 2019-2026.
Company Filing History:
Years Active: 2019-2026
Title: Sara Ghorashian: Innovator in Cancer Treatment
Introduction
Sara Ghorashian is a prominent inventor based in London, GB. She has made significant contributions to the field of cancer treatment through her innovative work on chimeric antigen receptors (CARs). With a total of 3 patents, her research focuses on developing targeted therapies for B cell malignancies.
Latest Patents
Sara's latest patents include a chimeric antigen receptor (CAR) that comprises a CD19-binding domain. This CAR features a heavy chain variable region (VH) with specific complementarity determining regions (CDRs) and a light chain variable region (VL) with its own set of CDRs. The sequences of these CDRs are critical for the CAR's functionality in targeting cancer cells. Additionally, the patent describes the use of cells containing such CARs in the treatment of cancer, particularly B cell malignancies.
Career Highlights
Throughout her career, Sara has worked with notable companies such as UCL Business Plc and Autolus Limited. Her experience in these organizations has allowed her to advance her research and contribute to the development of innovative cancer therapies.
Collaborations
Sara has collaborated with esteemed colleagues, including Martin Pulé and Leila Mekkaoui. These partnerships have enriched her research and expanded the impact of her work in the field of cancer treatment.
Conclusion
Sara Ghorashian is a trailblazer in the development of chimeric antigen receptors for cancer therapy. Her innovative patents and collaborations highlight her commitment to advancing medical science and improving patient outcomes.